文献速递消化系统肿瘤

伊立替康联合西妥昔单抗±维莫非尼治疗BRAF突变转移性结直肠癌的随机试验(SWOG S1406)

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).
PubMed 文献 · J Clin Oncol · 2020-12-23

结论:同时抑制EGFR和BRAF联合伊立替康对BRAFV600E突变结直肠癌有效。

要点

  • 联合组87%患者循环肿瘤DNA BRAFV600E变异等位基因频率下降,进展时获得性RAS改变发生率低。

核心结论

  • 同时抑制EGFR和BRAF联合伊立替康对BRAFV600E突变转移性结直肠癌有效。

主要发现

  • RNA分析提示治疗获益不依赖于既往建立的BRAF亚组或共识分子亚型。

临床怎么用

  • 对于既往治疗过的BRAFV600E突变转移性结直肠癌,可考虑伊立替康+西妥昔单抗联合维莫非尼方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: BRAFV600E mutations are rarely associated with objective responses to the BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC). Blockade of BRAFV600E by vemurafenib causes feedback upregulation of EGFR, whose signaling activities can be impeded by cetuximab. METHODS: One hundred six patients with BRAFV600E-mutated metastatic CRC previously treated with one or two regimens were randomly assigned to irinotecan and cetuximab with or without vemurafenib (960 mg PO twice daily). RESULTS: Progression-free survival, the primary end point, was improved with the addition of vemurafenib (hazard ratio, 0.50, P = .001). The response rate was 17% versus 4% (P = .05), with a disease control rate of 65% versus 21% (P < .001). A decline in circulating tumor DNA BRAFV600E variant allele frequency was seen in 87% versus 0% of patients (P < .001), with a low incidence of acquired RAS alterations at the time of progression. RNA profiling suggested that treatment benefit did not depend on previously established BRAF subgroups or the consensus molecular subtype. CONCLUSION: Simultaneous inhibition of EGFR and BRAF combined with irinotecan is effective in BRAFV600E-mutated CRC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kopetz S, Guthrie KA, Morris VK, et al. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol. 2020. PMID: 33356422. doi:10.1200/JCO.20.01994

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。